To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.
1) Patients must be ≥ 16 years of age;
2) Patients receiving haploidentical allo-HSCT;
3) Patients have to sign an informed consent form before the start of the research procedure.
1) Tandem transplantation or multiple transplantations;
2) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;
3) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.